These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 32006641

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Real-life safety and efficacy of vildagliptin as add-on to metformin in patients with type 2 diabetes in Turkey--GALATA study.
    Ayvaz G, Keskin L, Akin F, Dokmetas HS, Tasan E, Ar IB, Uren E, GALATA Study Group.
    Curr Med Res Opin; 2015 Apr; 31(4):623-32. PubMed ID: 25697921
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of vildagliptin: 52-week post-marketing surveillance of Japanese patients with type 2 diabetes in combination with other oral antidiabetics and insulin.
    Hayashi T, Murayama H, Shinfuku Y, Taniguchi T, Tsumiyama I, Oyama N.
    Expert Opin Pharmacother; 2020 Jan; 21(1):121-130. PubMed ID: 31689132
    [Abstract] [Full Text] [Related]

  • 7. Initial combination therapy with vildagliptin plus metformin in drug-naïve patients with T2DM: a 24-week real-life study from Asia.
    Chawla M, Kim TH, Mirasol RC, Faruque P, Cooke K, Hours-Zesiger P, Shete A.
    Curr Med Res Opin; 2018 Sep; 34(9):1605-1611. PubMed ID: 29764225
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Effect of vildagliptin on hsCRP and arterial stiffness in patients with type 2 diabetes mellitus.
    Zografou I, Sampanis C, Gkaliagkousi E, Iliadis F, Papageorgiou A, Doukelis P, Vogiatzis K, Douma S.
    Hormones (Athens); 2015 Sep; 14(1):118-25. PubMed ID: 25402372
    [Abstract] [Full Text] [Related]

  • 12. Re: Efficacy and Safety of Vildagliptin and Remogliflozin as Add-on Therapy to Metformin in Patients of Type 2 Diabetes Mellitus.
    Raza H, Bhutta ME, Siddique MH.
    Sultan Qaboos Univ Med J; 2024 Aug; 24(3):418-419. PubMed ID: 39234328
    [No Abstract] [Full Text] [Related]

  • 13. The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients.
    El-Naggar AR, Zaafar D, Elyamany M, Hassanin S, Bassyouni A, Abdel-Latif H.
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):254-261. PubMed ID: 30630371
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Translating science into clinical practice: focus on vildagliptin in combination with metformin.
    Barnett AH.
    Diabetes Obes Metab; 2009 May; 11 Suppl 2():18-26. PubMed ID: 19385980
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of a Fixed Dose Combination of Remogliflozin Etabonate and Vildagliptin in Patients with Type-2 Diabetes Mellitus: A Randomized, Active-Controlled, Double-Blind, Phase III Study.
    Khaladkar K, Mohan B, Khaladkar K, Suryawanshi S, Barkatestrong/Strong H.
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443373
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the Effectiveness and Safety of Vildagliptin Add-On to Metformin Versus Other Oral Dual Antidiabetes Agents in Patients with Type 2 Diabetes: The China Prospective Diabetes Study.
    Zang L, Han Y, Chen L, Hu D, Jin H, Yang N, Shi X, Liang L, Liu M, Fan H, Li Q, Mu Y.
    Diabetes Ther; 2019 Aug; 10(4):1391-1405. PubMed ID: 31222594
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.